Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

LaunchTrends: Anoro Ellipta (US) (Wave 2) | 2015

Login to access report north_east
Contact sales account_box

LaunchTrends: Anoro Ellipta Wave 2 is the second of a three-wave report series designed to track the postlaunch awareness, trial, and usage of Anoro Ellipta among pulmonologists for the treatment of chronic obstructive pulmonary disease (COPD) in the United States. This syndicated primary research report examines physicians’ perception at six months following the commercial availability of Anoro Ellipta. The report also investigates where Anoro Ellipta will fit into the treatment algorithm, likely patient candidates, perceived advantages and disadvantages of the product, and GlaxoSmithKline’s promotional efforts.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
north_east
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
north_east
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east